05:14 PM EST, 01/14/2025 (MT Newswires) -- Rapid Micro Biosystems ( RPID ) said Tuesday it expects Q4 revenue of about $8.2 million, up about 30% from a year earlier.

Two analysts polled by FactSet expect $7.6 million.

The company expects full-year 2024 revenue of about $28.1 million, up about 25% from a year earlier.

Two analysts surveyed by FactSet expect $27.5 million.

Rapid also said it is launching a collaboration with Lonza to integrate Rapid's Growth Direct systems and Lonza's MODA-EM module to create an environmental monitoring quality control product.

Lonza will deploy the solution across its cell and gene therapy manufacturing network, according to Rapid.

Rapid shares were rising nearly 15% in after-hours trading.